Clinical Pharmacokinetic Considerations in the Treatment of Patients with Leprosy
- 1 June 1989
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 16 (6) , 365-386
- https://doi.org/10.2165/00003088-198916060-00003
Abstract
No abstract availableKeywords
This publication has 98 references indexed in Scilit:
- The effect of clofazimine on the pharmacokinetics of rifampicin and dapsone in leprosyJournal of Antimicrobial Chemotherapy, 1986
- Clinical Pharmacokinetics of DapsoneClinical Pharmacokinetics, 1986
- DO ANTI-LEPROSY DRUGS REACH MYOBACTERIUM LEPRAE IN PERIPHERAL NERVES?The Lancet, 1981
- Sulfones and sulfonamides in dermatology todayJournal of the American Academy of Dermatology, 1979
- Clinical Pharmacokinetics of IsoniazidClinical Pharmacokinetics, 1979
- Clinical Pharmacokinetics of RifampicinClinical Pharmacokinetics, 1978
- RIFAMPICIN IN EARLY PREGNANCYThe Lancet, 1977
- Serum concentrations and antituberculosis activity of thiacetazoneTubercle, 1974
- The Effect Of Rifampicin And Dapsone On Experimental Mycobacterium Leprae Infections: Minimum Inhibitory Concentrations And Bactericidal ActionJournal of Medical Microbiology, 1972
- ABSORPTION AND EXCRETION OF 35S DAPSONE IN DERMATITIS HERPETIFORMISBritish Journal of Dermatology, 1970